Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia

Autor: Mario Ilić, Zeljka Jurekovic, Lada Zibar, Morana Tomljenović, Petra Dinjar-Kujundzic, Lorena Jemeršić, Mladen Knotek, Jelena Prpić, Anna Mrzljak, Marijana Gulin, Tatjana Vilibić-Čavlek, Irena Hrstić, Boris Kudumija, Branko Kolarić
Rok vydání: 2019
Předmět:
Male
medicine.medical_specialty
Croatia
Urology
medicine.medical_treatment
030232 urology & nephrology
Seroprevalence
030204 cardiovascular system & hematology
medicine.disease_cause
03 medical and health sciences
0302 clinical medicine
Hepatitis E virus
hepatitis E virus
seroprevalence
haemodialysis
risk factors
BIOMEDICINA I ZDRAVSTVO. Javno zdravstvo i zdravstvena zaštita
Renal Dialysis
Residence Characteristics
Risk Factors
Seroepidemiologic Studies
Internal medicine
Medicine
Area of residence
Humans
In patient
Blood Transfusion
Significant risk
Hepatitis Antibodies
Dialysis
biology
business.industry
BIOMEDICINE AND HEALTHCARE. Public Health and Health Care
virus diseases
Middle Aged
Hepatitis E
medicine.disease
Haemodialysis
Risk factors
Immunoglobulin M
Nephrology
Immunoglobulin G
biology.protein
Kidney Failure
Chronic
RNA
Viral
Female
Antibody
business
Zdroj: International Urology and Nephrology
Volume 52
Issue 2
ISSN: 1573-2584
0301-1623
Popis: Purpose Data on the seroprevalence of hepatitis E virus (HEV) in heamodialysis (HD) patients are conflicting, ranging from 0 to 44%. The aim of this study was to determine the HEV seroprevalence and risk factors among HD patients in Croatia. Methods A total of 394 HD patients from six medical facilities in five Croatian cities (three sites in the continental and three sites in the coastal region) were tested for HEV IgM/IgG antibodies using an enzyme-linked immunosorbent assay. Additionally, all samples were tested for HEV RNA by RT-PCR. Sociodemographic data and risk factors were collected using a questionnaire. Results HEV IgG antibodies were detected in 110 (27.9%) patients. The seroprevalence varied significantly between dialysis centres, ranging from 5.2 to 43.4% (p = 0.001). HEV IgM antibodies were found in 0.04% of IgG positive patients. All patients tested negative for HEV RNA. Factors associated with HEV IgG seropositivity were age > 60 years (OR 8.17 ; 95% CI 1.08–62.14), living in the continental parts of the country (OR 2.58 ; 95% CI 1.55– 4.30), and transfusion of blood products (OR 1.66 ; 95% CI 1.01–2.73). After adjusting for age and gender, patients from continental regions had higher odds of HEV seropositivity compared to patients from coastal regions (OR 2.88 ; 95% CI 1.71–4.85) and those who had RBC transfusions (OR 1.70, 95% CI 1.02–2.69) compared to those who did not. Conclusion The study showed a high HEV seropositivity among HD patients in Croatia, with significant variations between geographical regions. Continental area of residence and RBC transfusion were the most significant risk factors for HEV seropositivity. Due to the high seroprevalence, routine HEV screening among HD patients, especially in transplant candidates should be considered.
Databáze: OpenAIRE
Externí odkaz: